| Literature DB >> 25759014 |
Todd W Ridky1, George Cotsarelis2.
Abstract
In this issue of Cancer Cell, two complementary papers by Atwood and colleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO) inhibitor vismodegib frequently harbor SMO mutations that limit drug binding, with mutations at some sites also increasing basal SMO activity.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25759014 DOI： 10.1016/j.ccell.2015.02.009
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743